Lupin Enters into Deal with Takeda to Commercialise Vonoprazan

Hyderabad: Global pharma major Lupin Limited has announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited, to commercialise Vonoprazan tablets in the Indian market. The drug will be marketed under the brand name Lupin’s Lupivon® and will be available in two strengths - 10 mg and 20 mg.

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.

"We are very pleased to commercialise Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients,” said, Rajeev Sibal, President India Region Formulations, Lupin.

Acid Peptic Disorder (APD) which includes Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), is a highly prevalent disorder in India. While prevalence of GERD ranges from 5 per cent to 28.5 per cent, PUD has prevalence in the range of ~ 8 per cent. Risk factors for GERD include old age, high body mass index (BMI), non-vegetarian diet, tea/coffee intake, smoking and alcohol consumption.